Licensing of Alemtuzumab
February 13, 2017 | in
Alemtuzumab reduces disease activity in previously untreated patients with …
Alemtuzumab reduces disease activity in previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety of alemtuzumab compared with interferon beta 1a in patients who have relapsed despite first-line treatment. Our work has led to the licensing of Alemtuzumab in the European Union and Mexico as a first line treatment for active relapsing- remitting multiple sclerosis, with second line licences in Canada and Australia. In work not supported by commercial funding we have shown that the principal adverse effect of alemtazumab, secondary autoimmunity, occurs when the immune system reconstitute by homeostatic proliferation of residual lymphocytes.
